International Clinical Trial: A Single-Center, Prospective, Single-Arm Clinical Study of Serplulimab Combined with Chemotherapy as Neoadjuvant Therapy for 3 Cycles in Resectable Stage II-IIIA NSCLC

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133409) titled 'A Single-Center, Prospective, Single-Arm Clinical Study of Serplulimab Combined with Chemotherapy as Neoadjuvant Therapy for 3 Cycles in Resectable Stage II-IIIA NSCLC' on Sept. 26.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University

Condition: Non-small-cell lung cancer

Intervention: Experimetal group:Serplulimab combined with chemotherapy (paclitaxel/nab-paclitaxel and platinum). Serplulimab: fixed dose 300 mg, intravenous infusion over 30-90 min chemotherapy administered after an interval of at least 30 min

Recruitment Sta...